Taysha Gene Therapies (NASDAQ:TSHA) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA - Free Report) in a report published on Wednesday, Benzinga reports. Needham & Company LLC currently has a $7.00 target price on the stock.

TSHA has been the topic of a number of other reports. Jefferies Financial Group restated a buy rating and set a $8.00 price target (up from $2.00) on shares of Taysha Gene Therapies in a research report on Tuesday. Cantor Fitzgerald restated an overweight rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday. Canaccord Genuity Group reiterated a buy rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Chardan Capital boosted their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a buy rating in a research note on Thursday, March 21st. Finally, Piper Sandler started coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They issued an overweight rating and a $9.00 target price for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of Buy and an average price target of $7.00.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA traded up $0.54 during midday trading on Wednesday, hitting $3.11. The stock had a trading volume of 4,684,978 shares, compared to its average volume of 2,449,883. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54. The stock has a 50 day simple moving average of $2.61 and a 200-day simple moving average of $2.11. The company has a market capitalization of $581.63 million, a PE ratio of -4.48 and a beta of 0.37. Taysha Gene Therapies has a 1 year low of $0.50 and a 1 year high of $3.89.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. During the same period in the prior year, the company posted ($0.28) earnings per share. On average, sell-side analysts expect that Taysha Gene Therapies will post -0.39 EPS for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds have recently modified their holdings of the business. Howard Capital Management Inc. purchased a new stake in Taysha Gene Therapies in the fourth quarter valued at approximately $25,000. Victory Capital Management Inc. acquired a new position in Taysha Gene Therapies during the 4th quarter worth about $28,000. Dynamic Technology Lab Private Ltd purchased a new position in Taysha Gene Therapies during the 4th quarter valued at about $31,000. China Universal Asset Management Co. Ltd. acquired a new position in Taysha Gene Therapies in the 4th quarter valued at about $38,000. Finally, Lee Financial Co purchased a new stake in Taysha Gene Therapies during the third quarter worth about $63,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.